GlobeNewswire: World Heart Corporation Contains the last 10 of 14 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:20:42ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2012/03/29/472019/250662/en/HeartWare-International-Expands-Intellectual-Property-and-Technology-Portfolio-Through-Definitive-Agreement-to-Acquire-World-Heart-Corporation-for-US-8-Million.html?f=22&fvtc=4&fvtv=11272HeartWare International Expands Intellectual Property and Technology Portfolio Through Definitive Agreement to Acquire World Heart Corporation for US$8 Million2012-03-29T22:55:00Z<![CDATA[FRAMINGHAM, Mass. and SALT LAKE CITY, March 29, 2012 (GLOBE NEWSWIRE) -- HeartWare International, Inc. (Nasdaq:HTWR) (ASX:HIN), which develops and manufactures miniaturized ventricular assist devices, and World Heart Corporation (Nasdaq:WHRT), which has been engaged in the development of left ventricular assist devices, announced today that they have entered into a definitive merger agreement under which HeartWare will acquire WorldHeart for consideration of US$8 million, which will be paid in shares of HeartWare common stock or cash, at HeartWare's election.]]>https://www.globenewswire.com/news-release/2011/07/29/452580/227966/en/WorldHeart-Will-End-Its-Levacor-R-VAD-Program-and-Will-Focus-on-Developing-Its-Next-Generation-MiFlow-TM-Miniature-Ventricular-Assist-Device.html?f=22&fvtc=4&fvtv=11272WorldHeart Will End Its Levacor(R) VAD Program and Will Focus on Developing Its Next-Generation MiFlow(TM) Miniature Ventricular Assist Device2011-07-29T16:00:00Z<![CDATA[SALT LAKE CITY, July 29, 2011 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2011/02/09/439683/213240/en/WorldHeart-Pauses-Enrollment-in-the-Levacor-R-VAD-Bridge-To-Transplant-Study.html?f=22&fvtc=4&fvtv=11272WorldHeart Pauses Enrollment in the Levacor(R) VAD Bridge-To-Transplant Study2011-02-09T13:55:00Z<![CDATA[SALT LAKE CITY, Feb. 9, 2011 (GLOBE NEWSWIRE) -- World Heart Corporation (WorldHeart) (Nasdaq:WHRT), a developer of mechanical circulatory systems, announced today that it has paused enrollment in its Levacor Ventricular Assist Device (VAD) Bridge-To-Transplant (BTT) Study pending U.S. Food and Drug Administration (FDA) review and approval of the previously announced device refinements.]]>https://www.globenewswire.com/news-release/2011/01/12/437663/210916/en/WorldHeart-Announces-Levacor-R-VAD-Implant-at-Tampa-General-Hospital-Enrollment-in-Bridge-to-Transplant-Study-Continues-to-be-Slow-as-WorldHeart-Makes-Refinements-to-Levacor-VAD.html?f=22&fvtc=4&fvtv=11272WorldHeart Announces Levacor(R) VAD Implant at Tampa General Hospital; Enrollment in Bridge-to-Transplant Study Continues to be Slow as WorldHeart Makes Refinements to Levacor VAD2011-01-12T14:00:00Z<![CDATA[SALT LAKE CITY, Jan. 12, 2011 (GLOBE NEWSWIRE) -- World Heart Corporation (WorldHeart) (Nasdaq:WHRT), a developer of mechanical circulatory systems, announced today that Tampa General Hospital (Tampa General) in Tampa, Florida has successfully implanted its first Levacor Ventricular Assist Device (VAD). Tampa General is the sixth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the 15]]>https://www.globenewswire.com/news-release/2010/12/06/435603/208359/en/Levacor-VAD-R-Hemocompatibility-Analysis-Presented-at-European-Mechanical-Circulatory-Support-Summit.html?f=22&fvtc=4&fvtv=11272Levacor VAD(R) Hemocompatibility Analysis Presented at European Mechanical Circulatory Support Summit2010-12-06T14:00:00Z<![CDATA[Preservation of an Important Blood Factor to Prevent Bleeding Observed SALT LAKE CITY, Dec. 6, 2010 (GLOBE NEWSWIRE) -- World Heart Corporation (WorldHeart) (Nasdaq:WHRT), a developer of mechanical circulatory systems, today announced that an investigator-initiated study that includes patients who had received the Levacor ventricular assist device (VAD) was the subject of a presentation in the Emerging New Technologies Section at the Fifth European Mechanical Circulatory Support Summit. Preliminary clinical data suggests that the Levacor VAD does not cause acquired von Willebrand Factor (vWF) deficiency, a condition that is linked to serious bleeding disorders]]>https://www.globenewswire.com/news-release/2010/10/20/431944/204195/en/World-Heart-Corp-Completes-Private-Placement-of-25-3-Million.html?f=22&fvtc=4&fvtv=11272World Heart Corp. Completes Private Placement of $25.3 Million2010-10-20T13:00:00Z<![CDATA[SALT LAKE CITY, Oct. 20, 2010 (GLOBE NEWSWIRE) -- World Heart Corporation (WorldHeart) (Nasdaq:WHRT), a developer of mechanical circulatory systems, announced today that it has completed its previously announced private placement of common stock and warrants to purchase common stock. Gross proceeds from the offering were approximately $25.3 million. Proceeds from the private placement are expected to be used for general corporate and working capital purposes.]]>https://www.globenewswire.com/news-release/2010/10/14/431546/203743/en/World-Heart-Corp-to-Raise-25-3-Million-in-Private-Placement.html?f=22&fvtc=4&fvtv=11272World Heart Corp. to Raise $25.3 Million in Private Placement2010-10-14T13:09:53Z<![CDATA[SALT LAKE CITY, Oct. 14, 2010 (GLOBE NEWSWIRE) -- World Heart Corporation (WorldHeart) (Nasdaq:WHRT), a developer of mechanical circulatory systems, announced today that it has obtained commitments from certain new and existing institutional investors, including Venrock Associates, New Leaf Venture Partners and the Special Situations Funds, to purchase approximately $25.3 million of its common stock in a private placement. WorldHeart has entered into a securities purchase agreement with the investors pursuant to which WorldHeart will sell an aggregate of 11,850,118 shares of its common stock and warrants to purchase up to 11,850,118 additional shares of common stock. Each unit, consisting of one share of common stock and one warrant, to purchase one share of common stock, will be sold for a purchase price of $2.135. The private placement is subject to customary closing conditions and is expected to close during the week of October 18, 2010. Lazard Capital Markets LLC and Wedbush PacGrow Life Sciences acted as the placement agents for the offering.]]>https://www.globenewswire.com/news-release/2010/08/16/427695/199385/en/WorldHeart-Announces-Levacor-VAD-Implant-at-Massachusetts-General-Hospital.html?f=22&fvtc=4&fvtv=11272WorldHeart Announces Levacor VAD Implant at Massachusetts General Hospital2010-08-16T13:00:00Z<![CDATA[SALT LAKE CITY, Aug. 16, 2010 (GLOBE NEWSWIRE) -- World Heart Corporation (WorldHeart) (Nasdaq:WHRT), a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital (Mass General) in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.]]>https://www.globenewswire.com/news-release/2010/08/12/427531/199190/en/WorldHeart-Appoints-Dr-Monica-Hope-as-Vice-President-of-Clinical-Affairs.html?f=22&fvtc=4&fvtv=11272WorldHeart Appoints Dr. Monica Hope as Vice President of Clinical Affairs2010-08-12T13:00:00Z<![CDATA[SALT LAKE CITY, Aug. 12, 2010 (GLOBE NEWSWIRE) -- World Heart Corporation (WorldHeart) (Nasdaq:WHRT), a developer of mechanical circulatory systems, announced the appointment of Dr. Monica Hope as Vice President of Clinical Affairs reporting to Dr. John Woodard, Sr. VP of Scientific Affairs. Dr. Hope will be responsible for conducting the current and future clinical trials with WorldHeart's products.]]>https://www.globenewswire.com/news-release/2010/08/03/426697/198267/en/WorldHeart-Announces-Tenth-Levacor-TM-VAD-Implant-in-U-S-BTT-Study.html?f=22&fvtc=4&fvtv=11272WorldHeart Announces Tenth Levacor(TM) VAD Implant in U.S. BTT Study2010-08-03T13:00:00Z<![CDATA[SALT LAKE CITY, Aug. 3, 2010 (GLOBE NEWSWIRE) -- World Heart Corporation (WorldHeart) (Nasdaq:WHRT), a developer of mechanical circulatory support systems, announced today that the tenth implant of the Levacor™ Venticular Assist Device (VAD) was performed in the Bridge-to-Transplant (BTT) clinical study.]]>